XOMA Earns $9M Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM for Relapsed or Refractory BRAF-...
XOMA Corporation announced it has earned a $9 million milestone related to the U.S. Food and Drug Administration’s (FDA) approval of Day One Biopharmaceuticals’ New Drug Application (NDA) for OJEMDA™ (tovorafenib) for the treatment of patients 6 months of …